E-viri
PDF
Recenzirano
Odprti dostop
-
Finn, Richard S; Qin, Shukui; Ikeda, Masafumi; Galle, Peter R; Ducreux, Michel; Kim, Tae-You; Kudo, Masatoshi; Breder, Valeriy; Merle, Philippe; Kaseb, Ahmed O; Li, Daneng; Verret, Wendy; Xu, Derek-Zhen; Hernandez, Sairy; Liu, Juan; Huang, Chen; Mulla, Sohail; Wang, Yulei; Lim, Ho Yeong; Zhu, Andrew X; Cheng, Ann-Lii
New England journal of medicine/The New England journal of medicine, 05/2020, Letnik: 382, Številka: 20Journal Article
In patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab was associated with better progression-free and overall survival outcomes, response rate, and preservation of quality of life than sorafenib. Serious toxic effects were noted in 38% of patients, similar to that seen in previous studies of these agents.
